Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2629356 | 0.86 | LSS (0.59) | LSSMTORHDAC3HDAC1HDAC2 | |
| SCHEMBL4576236 | 0.83 | MTOR (0.54) | LSSMTORHDAC3HDAC1HDAC2 | |
| SCHEMBL24575984 | 0.82 | MTOR (0.69) | LSSMTORHDAC3HDAC1HDAC2 | |
| SCHEMBL3630497 | 0.81 | LSS (0.55) | LSSMTORHDAC3HDAC1HDAC2 | |
| SCHEMBL15682657 | 0.81 | MTOR (0.52) | LSSMTORHDAC3HDAC1HDAC2 | |
| SCHEMBL17231401 | 0.81 | MLYCD (0.60) | MAPK14P2RX7 | |
| SCHEMBL1695141 | 0.80 | MTOR (0.58) | LSSMTORHDAC3HDAC1HDAC2 | |
| SCHEMBL934145 | 0.79 | HDAC3 (0.60) | LSSMTORHDAC3HDAC1HDAC2 | |
| SCHEMBL21387743 | 0.79 | HDAC3 (0.59) | LSSMTORHDAC3HDAC1HDAC2 | |
| SCHEMBL3897948 | 0.79 | CYP2C9 (0.59) | LSSMTORHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | claimed |
| WO-2009045083-A2 | COMBINATION THERAPY FOR NEUROPROTECTION | S.H. PHARMA., LTD (KR) | 2009-04-09 | — | — | WO | claimed |
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216749-A1 | Combination Therapy for Neuroprotection | MPO, BDNF, NLN | LSS 4839/4885MTOR 997/4885HDAC3 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.